Tag - Akston Biosciences

Todd Zion, PhD, CEO and Repeat Founder, “Magical Proteins”

Ziad2022-11-25T14:00:28-05:00 Welcome to Angel Invest Boston, conversations with Boston's most interesting founders and angels. I'm Sal Daher, an angel investor who is very curious to find out how to best build really great technology companies. Today, I am privileged to have with me as my guest, Todd Zion. Founder of Akston Bio, which is a very interesting company. Todd is a successful second-time founder. He had an exit to Merck, a $500 million exit to Merck of a diabetes therapy, which...

Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine

Ziad2022-11-25T14:00:28-05:00 Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate. Fifty-two volunteers will receive either one- or two-dose regimens as part of the Phase II trial conducted at University Medical Center Groningen (UMCG), one of the largest hospitals in the Netherlands. Read more >>

Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-Stable COVID-19 Vaccine at Global Scale

Ziad2022-11-25T14:00:29-05:00 Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, today announced a commercial agreement with Seppic S.A., a supplier of specialty healthcare ingredients, for the supply of adjuvant for use in Akston’s COVID-19 Fc fusion protein vaccine candidate, AKS-452. Read more >>

Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

Ziad2022-11-25T14:00:29-05:00 Today, Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced positive results from a 60-subject, open-label, Phase I trial of AKS-452, its protein subunit, room temperature stable, COVID-19 vaccine candidate. Read more >>

New vaccines should help India fill gaps in vaccination campaign

Ziad2022-11-25T14:00:29-05:00 ...One such vaccine is the AKS-452 jab developed by US-based Akston Biosciences, which is currently undergoing Phase I/II trials in the Netherlands. Read more >>

Amid surging Covid-19 cases, second gen vaccines raise hopes across the Asia-Pacific

Ziad2022-11-25T14:00:29-05:00 The United Nations High Commissioner for Refugees sounded the alarm at the beginning of this month on the rapidly deteriorating circumstances of refugees and asylum seekers in Asia... After the first spate of vaccine approvals at the beginning of this year, a slew of new vaccines will not only bolster global supply, thereby improving access, but also offer an improvement on extant vaccines... One such second-generation vaccine, produced by US-based Akston Biosciences, is especially well-suited for hot regions such as ASEAN because...

The Right Shots In The Right Places

Ziad2022-11-25T14:00:30-05:00 Row Covid-19 or Coronavirus vaccine flasks on white background Every safe and effective Covid-19 vaccine is helping to end the global pandemic. But that doesn't mean they're all the same. To succeed globally, though, we can't just focus on what works best on our own shores. A temperature-sensitive vaccine shipped to a facility without freezers will go to waste. Scheduling two doses isn't feasible for every population. In developing countries, these challenges can be acute. More remarkably, Akston Biosciences has begun...

Akston Biosciences and LakePharma Announce Strategic Partnership to Manufacture Second-Generation COVID-19 Vaccine

Ziad2022-11-25T14:02:04-05:00 Akston Biosciences, which develops new classes of biologic therapeutics, and LakePharma, a leading U.S.-based CRDMO serving the biotechnology community, announced today that they have established a strategic partnership. Read more >>

TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452, an innovative anti-COVID-19 vaccine

Ziad2022-11-25T14:02:28-05:00 BEVERLY, Mass., USA & GRONINGEN, the Netherlands, Sept. 01, 2020 Today, TRACER Europe B.V., a Clinical Research Organization (CRO) specializing in fast-track solutions for testing innovative biologic medicines, announced that it will support Akston Biosciences Inc., a leader in the development of novel Fc fusion protein therapeutics, in the Phase 1 clinical testing in the Netherlands of Akston’s lead COVID-19 vaccine candidate, AKS-452. Read more >>